WHO Prequalification

WHO Prequalification (PQ) is the World Health Organization’s technical assessment and listing program for priority health products. It evaluates whether a product consistently meets international expectations for quality, safety, performance, and programmatic suitability, then lists acceptable products on the WHO Prequalified Products List. Procurement agencies, donors, and ministries of health use this signal to de-risk tenders and standardize expectations in low- and middle-income settings.

The program is organized into product streams—medicines, vaccines, in vitro diagnostics (IVDs), and vector-control products—and operates through targeted Expressions of Interest (EOIs). Applicants submit a structured dossier and undergo rigorous scientific assessment and site inspections or reliance-based verification when credible oversight exists. Passing products are listed publicly, enabling pooled or donor-financed procurement to move quickly without sacrificing independent assurance.

WHO PQ is not a national marketing authorization. Instead, it is a convergence mechanism that aligns with global standards and collaborates with Stringent Regulatory Authorities (SRAs), WHO-Listed Authorities (WLAs), and PIC/S-participating inspectorates. The emphasis is not only on dossier adequacy but also on manufacturability, cold-chain integrity where applicable, and programmatic suitability under real-world conditions.

For manufacturers, a PQ listing is a badge of technical rigor and an operational commitment. It entails maintaining mature quality systems, managing changes in a traceable manner, responding promptly to quality signals, and supporting deployment at scale. Sponsors that institutionalize a robust quality assurance process are best positioned to sustain compliance and supply reliability over the product lifecycle.

The technical foundation of WHO PQ draws from WHO guidance and the ICH Quality suite. For medicines and active pharmaceutical ingredients (APIs), WHO GMP expectations are anchored in the Technical Report Series (TRS) 1044:2022, which sets out contemporary manufacturing system controls and inspection practices. ICH Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System) define lifecycle expectations, while ICH Q1, Q2, and the Q3 series cover stability, analytical validation, and impurities.

For IVDs, ISO 13485 provides the QMS baseline, complemented by analytical and clinical performance evidence, design controls, risk management, usability engineering, labeling, and production validation aligned to intended use and target settings. For vaccines and vector-control products, WHO technical guidance emphasizes manufacturing consistency, lot-release systems, validated storage and transport controls, and evidence of programmatic suitability under realistic conditions.

PQ relies, when appropriate, on credible prior work by SRAs and WLAs. Reliance can include leveraging assessment reports, inspection outputs from PIC/S-participating inspectorates, and recognized lot-release systems. WHO retains responsibility for its own conclusion, applying risk-based verification to ensure that evidence matches the claimed context of use, supply footprint, and demand scale.

Crucially, PQ does not replace national registration. Some regulators may accept PQ outcomes within reliance frameworks, but the program’s mandate is to assure eligibility for global procurement rather than to confer market authorization. Sponsors should plan a regulatory strategy that sequences national submissions and PQ in a way that leverages convergence without assuming automatic mutual recognition.

Risk management should be explicit and demonstrable throughout dossier development and review. Sponsors that embed ICH Q9 principles and maintain an ISO 13485–appropriate documentation architecture for device portfolios are better able to address WHO’s targeted queries and minimize clock stops.

PQ targets products that address priority public-health needs, including HIV, tuberculosis, malaria, reproductive health, maternal and child health, and immunization. WHO periodically publishes Expressions of Interest (EOIs) that define eligible product categories, the intended populations, and the data expected. EOIs may specify finished dosage forms, vaccine categories, diagnostic technologies, vector-control modalities, and sometimes pathways for active substances.

Manufacturers of finished products, contract manufacturing organizations (CMOs), and, when specified, API suppliers may apply. Eligibility also depends on operational readiness, including mature quality systems, validated processes, and the capacity to sustain supply in tender-driven, donor-financed markets. For diagnostics, labeling and Instructions for Use should be adapted to target settings, languages, and training profiles to reduce use errors and enhance field performance.

EOIs are dynamic, reflecting evolving public-health priorities, evidence standards, and technology classes. Sponsors should monitor new and revised EOIs to ensure alignment between product claims, manufacturing capabilities, and the evidence required. Where applicable, stability protocols should reflect climatic zones encountered in target markets and be planned as part of a risk-managed stability program rather than a one-time study.

The PQ pathway typically begins with an EOI that sets the scope, data expectations, and administrative requirements for a target product category. Prospective applicants assess eligibility, conduct a gap analysis versus WHO GMP, ICH, or ISO 13485 expectations, and define a submission plan that sequences module readiness, site preparedness, and interdependencies with national filings.

Applicants compile a structured dossier that substantiates quality, safety, efficacy or performance, and programmatic suitability. Scientific assessment is conducted by international experts and often proceeds in parallel with site inspections or QMS audits. Deficiencies are issued as written queries; sponsors respond with data, updated risk assessments, and corrective or preventive actions that are cross-referenced to the submission’s claims and manufacturing reality.

Where credible oversight exists, WHO may employ reliance. This can include leveraging assessment or inspection outputs from WHO-Listed Authorities and PIC/S-participating inspectorates, supplemented by targeted verification of product- and site-specific risks. A successful outcome leads to public listing on the WHO Prequalified Products List and eligibility for procurement pathways that reference PQ.

Effective execution depends on disciplined dossier architecture, transparent document control, readiness for inspection, and cross-functional responsiveness to queries. Sponsors that pre-plan evidence retrieval, data integrity checks, and change histories reduce the risk of prolonged clock stops or post-inspection corrective actions. Post-listing, sponsors maintain surveillance, change control, and tender responsiveness to sustain impact.

Medicines submissions typically follow a CTD-style structure that demonstrates product and process understanding, control strategy, and, where required, clinical interchangeability. Quality modules should detail API synthesis and control, finished-product specifications, process description, validation strategy, and release/stability analytics. Stability protocols should cover climatically relevant zones per ICH Q1A stability storage conditions, and impurity justifications should track the ICH Q3A and ICH Q3B frameworks.

Analytical validation should follow ICH Q2 principles with method suitability established for intended matrices and ranges. Bioequivalence or clinical evidence must be protocol-justified and congruent with target labeling, posology, and patient populations in the EOI remit. The totality of evidence should connect design intent to routine control, with clear rationales supported by risk management and change history.

Vaccine dossiers place strong emphasis on manufacturing consistency, potency and stability-indicating methods, validated cold-chain systems, and lot-release traceability. Evidence of programmatic suitability in realistic transport and use conditions is essential. For IVDs, ISO 13485–conforming QMS documentation, design controls, risk management, analytical sensitivity and specificity, clinical performance in representative settings, and human-factors/usability validation are central, alongside accurate labeling and Instructions for Use.

Vector-control product dossiers should establish efficacy and durability against target vectors under field-relevant conditions and demonstrate manufacturing controls that ensure uniformity and safety. Across all streams, claims in the submission must match labels, manufacturing realities, and supplier controls. A coherent narrative linking development data, validation evidence, and ongoing lifecycle governance will withstand scrutiny better than a fragmented file.

Inspections under PQ assess compliance with WHO GMP for medicines and vaccines and with ISO 13485 for IVD manufacturers. Scope and depth are risk-based, considering product criticality, process complexity, and the anticipated supply footprint. When credible oversight exists—such as inspections from WHO-Listed Authorities or PIC/S-participating inspectorates—WHO may leverage those outputs while performing targeted verification to confirm applicability to the specific product and site.

A mature QMS is a prerequisite for sustained listing. Sponsors should demonstrate closed-loop deviation and CAPA management, supplier qualification and oversight, change control mapped to validated states, and ongoing process performance monitoring. Evidence packages should show that quality controls are not episodic but institutionalized across sites, including CMOs and critical suppliers, with clear contractual and technical governance.

Data integrity remains a cross-cutting expectation. Records should be attributable, legible, contemporaneous, original, and accurate, with validated computerized systems where used. Sponsors that embed data integrity by design principles and maintain defensible audit trails can respond quickly to WHO queries, justify reliance scenarios, and minimize the need for extensive on-site re-verification.

Importantly, reliance does not dilute responsibility. WHO must still reach its own conclusion on suitability for global procurement. Sponsors should anticipate targeted questions that connect prior approvals or inspections to the precise formulation, manufacturing configuration, scale, and markets included in the EOI.

PQ listing is not the end of regulatory scrutiny. Post-listing, manufacturers must maintain continuous compliance and seek prior approval for significant changes. Examples include site transfers, critical raw-material changes, major process modifications, and label changes that could affect safe or effective use. Routine changes should be categorized and justified according to risk, supported by validation and comparability evidence.

Complaint handling, vigilance reporting, and targeted post-market studies are integral to ongoing assurance. For IVDs, field safety corrective actions must be timely and comprehensively documented; for medicines and vaccines, quality defect investigations must be thorough and traceable to batch records and release decisions. Sponsors should predefine escalation pathways that integrate tender timelines and public-health risk.

Supply continuity is a programmatic imperative. Donor-financed tenders can generate demand surges that require capacity planning, dual sourcing of critical materials, and robust logistics. Sponsors should monitor signals from procurement agencies, maintain safety stocks where prudent, and ensure that lifecycle changes do not destabilize validated supply chains.

A disciplined approach to surveillance and change control reduces corrective actions and safeguards listing status. Building feedback loops from the field and integrating them with risk registers, validation strategies, and labeling governance keeps evidence aligned with real-world performance and procurement expectations, strengthening post-market surveillance credibility.

A recurring pitfall is treating PQ as a one-off file assembly. WHO assesses whether the evidence, controls, and supply capability will hold under real-world tender pressures. If the control strategy is fragile, supplier oversight is informal, or labels do not match field conditions, queries and corrective actions will follow. Another frequent issue is submitting data that does not correspond to the exact manufacturing configuration or scale proposed for procurement.

Sponsors sometimes conflate PQ with marketing authorization. PQ can be leveraged by regulators in reliance pathways, but it is not, by itself, a grant of national market entry. Conversely, some teams assume SRA approval renders PQ automatic. WHO may bridge to SRA or WLA outputs, yet it still verifies alignment with the EOI, intended use, and supply context—including storage conditions, training needs, and distribution pathways.

The reliance ecosystem around PQ includes WLAs, SRAs, and the PIC/S network. EMA, FDA, and other SRAs provide high-value source assessments; PIC/S enables convergence of inspection practices. EudraLex codifies the EU GMP framework that many inspectors reference. Understanding how these elements connect allows sponsors to present prior work in a way that is both efficient and acceptable to WHO.

• Mismatch between dossier claims, labeling, and manufacturing reality, leading to avoidable queries
• Inadequate risk assessments or validation plans for proposed changes during review
• Insufficient usability and language adaptation for IVD Instructions for Use in target countries
• Assuming SRA approval alone guarantees PQ without targeted verification
• Underestimating supply-chain robustness and tender-driven volume swings
• Stability studies not aligned to climatic conditions or intended logistics profiles
• Fragmented supplier oversight that obscures traceability and comparability

Proactive mitigation includes aligning study designs to target conditions, formalizing supplier controls, ensuring climatic suitability of stability protocols, and demonstrating how reliance outputs map to the specific PQ submission. Sponsors should explicitly address procurement realities, training needs, and logistics—in addition to regulatory conformance—to avoid late surprises.

Finally, tender strategies should anticipate delivery and warehousing constraints in target markets. Risk-based buffers, agreed lead times, and diversified transportation plans can prevent the quality- or compliance-erosion that occurs when production schedules are compressed beyond validated ranges, strengthening supply chain risk management outcomes.

PQ aligns dossier and inspection expectations with established international norms so that procurement decisions can lean on convergent quality systems. ICH guidelines underpin pharmaceutical development, risk management, quality system maturity, and analytical credibility. ISO 13485 shapes device QMS structure, document control, design controls, and production controls that translate into reliable IVD performance. For vaccines, WHO technical requirements and lot-release systems connect manufacturing consistency with public-health deployment.

At the inspection level, convergence with PIC/S facilitates mutual understanding of GMP risk control and allows reliance on participating inspectorates where appropriate. In the European Union, EudraLex provides codified GMP and GxP guidance that many authorities and auditors reference when examining pharmaceutical manufacturers. EMA scientific opinions and FDA approvals serve as high-credibility anchors for reliance pathways, though WHO still applies its own risk-based verification.

Procurement norms from UN agencies and donor consortia often reference PQ as an eligibility condition or a strong preference. This linkage creates an operational imperative for sponsors to maintain continuous compliance, plan for lifecycle changes, and protect data integrity under compressed tender timelines. Aligning internal governance to these norms ensures that evidence remains retrieval-ready and defensible.

Sponsors should view PQ not as a parallel regime but as a convergence bridge that translates global standards into procurement-grade assurance. Proving that controls are robust under real-world constraints—temperature excursions, language diversity, intermittent connectivity, and variable training levels—matters as much as textbook conformance to standards. This is where operational discipline and transparent evidence chains make the decisive difference.

WHO PQ favors organizations that can produce, govern, and retrieve evidence without delay. V5 Ultimate provides an integrated quality and manufacturing backbone that links batch data, validation packages, supplier controls, audit trails, and field feedback into a single, query-ready record. This enables sponsors to present a coherent narrative that connects development intent to routine control and real-world performance.

Submission teams can coordinate dossier authoring and change histories with traceable workflows, while operations maintain validated states and continuous monitoring. Inspection teams gain line-of-sight from master data to executed records, and lifecycle managers can demonstrate how post-listing changes are risk-assessed, validated, and communicated. The result is shorter response cycles, fewer clock stops, and more resilient supply execution under tender pressure.

For IVD portfolios, design control and usability outputs can be linked to manufacturing evidence and field signals. For medicines and vaccines, process performance monitoring and supplier oversight are anchored to a common data model that ties directly to PQ claims. Evidence retrieval is accelerated through granular search, structured metadata, and governing workflows that maintain integrity and traceability. When it is time to audit, teams can surface role-filtered views directly from V5 or share defensible exports with reviewers using the QMS capability.